Not many people are really able to keep things under tight wraps. Certainly, many a jailbird might be able to or the occasional secret agent perhaps, but at the latest when it comes to grandpas and grandmas, best friends or any typical gossips, information leaks are everywhere. Even in Hillary Clinton’s administration, much to the enjoyment of Wikileaks. However, in Düsseldorf a branch of trade is currently presenting leak-free products, guaranteed for 50 years. If only everyone were able to do what the valves on display at the Valve World Expo are capable of.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today congratulated trusted Edwards partner Dr. Albert Starr on receiving the 2015 Institut de France’s Grand Prix Scientifique in a Paris awards ceremony.
The Grand Prix is one of the largest prizes for scientific accomplishment and is considered the world’s most prestigious prize for cardiovascular research. The Institut’s board awarded Starr the Grand Prix in recognition of research that led to the world’s first successful artificial mitral valve implant in 1960. In the last 55 years, millions of patients around the world have benefitted from the emergence of the field of heart valve replacement and the many technological advances that followed.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7536851-france-grand-prix-starr-edwards/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, reported that The New England Journal of Medicine today published results from Cohort B of The PARTNER Trial, which studied the Edwards SAPIEN transcatheter heart valve for the treatment of severe aortic stenosis. The results of the trial successfully met the primary endpoints of all-cause mortality and mortality plus repeat hospitalization.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/44227/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and haemodynamic monitoring, announced the results of a pivotal clinical study of high-risk surgical patients with severe aortic stenosis treated in Cohort A of The PARTNER Trial. These data demonstrate that the study achieved its primary endpoint at one year, concluding that survival of patients treated with the Edwards SAPIEN transcatheter aortic valve was equivalent to those treated with surgical aortic valve replacement. The data were presented at the American College of Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New Orleans, LA, USA.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/48895/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them.
The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016.
To view the multimedia release go to:
Abbott today announced the U.S. Food and Drug Administration (FDA) approved the Masters HP™ 15mm rotatable mechanical heart valve, the world’s smallest mechanical heart valve, that will allow doctors to treat babies and toddlers in need of a mitral or aortic valve replacement. Until today, surgeons could only use a range of larger-sized valves to replace a pediatric heart valve that could not be repaired, and larger valves are often not suitable given the smaller size of children’s hearts. This dime-sized new valve is the first and only pediatric mechanical heart valve developed for newborns and infants, and offers hope for pediatric patients in urgent need of treatment who have no other approved options.
To view the multimedia release go to: